K-V Pharmaceutical Names Thomas Mchugh Chief Financial Officer
July 15, 2010 - July 15, 2010, St. Louis, MO. - K-V Pharmaceutical Company (NYSE: KVa/KVb) announced today that Thomas S. McHugh has been appointed Chief Financial Officer, effective immediately.

K-V Pharmaceutical Announces Resubmission to New Drug Application for Gestiva
July 13, 2010 - July 13, 2010, St. Louis, MO. - K-V Pharmaceutical Company (NYSE: KVa/KVb) (the "Company"), a specialty pharmaceutical company, announced today that it has been informed by Hologic, Inc. (NASDAQ: HOLX) that a resubmission to the FDA’s Complete Response action letter received in January 2009 has been submitted for Gestiva™ (hydroxyprogesterone caproate injection), 250 mg/mL. If approved, Gestiva, commonly referred to as "17P," would be the first and only FDA-approved drug for the prevention of preterm birth in women who are pregnant with a single baby and have spontaneously delivered a single baby preterm in the past.

K-V Pharmaceutical Company Announces the Election of New Independent Member to Board of Director
July 7, 2010 - July 7, 2010, St. Louis, MO. - KV KV Pharmaceutical Company (NYSE: KVa/KVb), a specialty pharmaceutical company, announced that Dr. David Sidransky was appointed as a new independent member of the Board of Directors by the K-V Pharmaceutical Company Board of Directors.

ETHEX Corporation Initiated Nationwide Voluntary Recall of a Single Lot of Hydromorphone HCl 2 mg Tablets
December 23, 2008

KV Pharmaceutical Voluntarily Suspends All Shipments of its Approved Tablet-form Drugs
December 23, 2008

For additional press releases, go to the press release archive.